Ascendis Pharma posts slide presentation on achondroplasia program updates

• Ascendis Pharma published a slide presentation outlining Week 78 Phase 2 COACH data for TransCon CNP plus TransCon hGH in achondroplasia.
• Combination therapy showed mean annualized growth velocity of 7.73 cm/year in treatment-naïve children at Week 78, height Z-score change +1.29.
• Previously TransCon CNP-treated cohort showed mean annualized growth velocity of 7.67 cm/year at Week 78, height Z-score change +1.10.
• Presentation also cited Week 104 pivotal ApproaCH monotherapy data showing durable height, proportionality, lower-limb alignment improvements, tolerability consistent with prior reports.
• U.S. YUVIWEL launch update through June 30 showed more than 170 unique enrollments, over 65% cleared for reimbursement; presentation posted at https://investors.ascendispharma.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.